Compare WOR & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WOR | EWTX |
|---|---|---|
| Founded | 1955 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 1994 | 2021 |
| Metric | WOR | EWTX |
|---|---|---|
| Price | $47.08 | $29.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $59.67 | $36.00 |
| AVG Volume (30 Days) | 108.5K | ★ 734.9K |
| Earning Date | 03-16-2026 | 05-27-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.25 | N/A |
| Revenue | ★ $1,153,762,000.00 | N/A |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $5.29 | N/A |
| P/E Ratio | $37.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.05 | $10.60 |
| 52 Week High | $70.91 | $31.82 |
| Indicator | WOR | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 21.52 | 51.58 |
| Support Level | N/A | $28.56 |
| Resistance Level | $56.72 | $31.12 |
| Average True Range (ATR) | 1.53 | 1.51 |
| MACD | -0.99 | -0.07 |
| Stochastic Oscillator | 8.75 | 53.56 |
Worthington Enterprises Inc is a designer and manufacturer of products and services, including manufactured metal products. The company operates under two reportable operating segments: Consumer Products and Building Products. The consumer Products business has a diverse product offering in the tools, outdoor living and celebrations categories, including propane-filled cylinders for torches, handheld torches, specialized hand tools, drywall tools, accessories and gas grills, and others. And the Building Products business engaged in providing pressurized containment solutions, providing critical components in the residential, non-residential, and repair and remodel end markets through essential categories. The company derives majority of the revenue from Building Products segment.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.